Document is current
Any future updates will be listed below
-
Authors
Floudas, Charalampos S. https://orcid.org/0000-0002-0020-237X
Goswami, Meghali
Donahue, Renee N.
Strauss, Julius
Pastor, Danielle M.
Redman, Jason M.
Brownell, Isaac
Turkbey, Evrim B.
Steinberg, Seth M.
Cordes, Lisa M.
Marté, Jennifer L.
Khan, Maheen H.
McMahon, Sheri
Lamping, Elizabeth
Manu, Michell
Manukyan, Manuk
Brough, Douglas E.
Lankford, Amy
Jochems, Caroline
Schlom, Jeffrey
Gulley, James L.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04432597 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C).
https://doi.org/10.1200/jco.2023.41.16_suppl.2628
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer
https://doi.org/10.1007/s00262-025-04009-z
Human papillomavirus vaccination and cervical cancer risk
https://doi.org/10.1136/bmj-2022-070115
483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers
https://doi.org/10.1136/jitc-2021-sitc2021.483
-
Funding
Funding for this research was provided by:
National Cancer Institute
- License Information
-
More Information
Article History
Received: 21 October 2024
Accepted: 3 March 2025
First Online: 21 March 2025
Declarations
:
: James L. Gulley and Julius Strauss are co-inventors on a patent for combination PDL1 and TGF-beta blockade in patients with HPV + malignancies. Amy Lankford and Douglas E. Brough are employees of Precigen, Inc., and hold stock ownership. Douglas E. Brough is a named inventor in patents pending.
: This study was conducted in accordance with all applicable regulatory requirements. All protocols were approved by the Institutional Review Board of the Center for Cancer Research at the National Cancer Institute. All participants provided written informed consent.
